Open AccessLuspatercept (Reblozyl)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.122
Subject(s) - reimbursement , vial , medicine , anemia , drug , beta thalassemia , thalassemia , family medicine , intensive care medicine , pharmacology , health care , political science , chemistry , law
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
This review assesses luspatercept (Reblozyl), 25 mg/vial, 75 mg/vial, powder for solution for subcutaneous injection.
Indication: For the treatment of adult patients with red blood cell transfusion-dependent anemia associated with beta-thalassemia.